Effect of Doxofylline on Reducing the Inflammatory Response in Mechanically Ventilated Rats with Chronic Obstructive Pulmonary Disease

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2021 Aug 25

PMID 34429595

Citations 4

Authors

Chu-Yun Liu

Jian-Hua Wu

Zhi-Yuan Chen

Yi Zhang

Chun-Ling Huang

Ai-Mei Lin

Xiao-Ting Xu

Xiao-Hua Gao

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the effect of doxofylline on reducing the inflammatory response in mechanically ventilated rats with chronic obstructive pulmonary disease (COPD).

Methods: A total of 40 eight-week-old male Sprague Dawley rats were randomly divided into four groups of 10 rats each: a control group (group C), a model group (group M), a model + natural saline group (group N), and a doxofylline group (group D). Then mechanical ventilation, drug intervention, and the extraction of the experimental material were performed in each group. Pulmonary tissue samples were taken after 120 minutes of mechanical ventilation and the pulmonary histopathological changes and the wet/dry (W/D) weight ratio of the pulmonary tissue were identified. The levels of tumor necrosis factor α (TNF-α) and interleukin 10 (IL-10) were detected using an enzyme-linked immunosorbent assay, and the expression levels of c-Jun-N-terminal kinase (JNK) and phosphorylated c-Jun N-terminal kinase (p-JNK) were detected using immunohistochemistry.

Results: Compared with group C, the pulmonary histopathology in groups M, N, and D showed typical changes associated with COPD. Furthermore, the W/D weight ratio and levels of TNF-α, JNK, and p-JNK in the pulmonary tissue increased in groups M, N, and D (P < 0.05), while the levels of IL-10 decreased (P < 0.05). Compared with group M, no statistically significant changes in the above indicators were detected in the pulmonary tissue of group N (P > 0.05). Compared with group N, the W/D weight ratio and levels of TNF-α, JNK, and p-JNK in the pulmonary tissue decreased in group D (P < 0.05), while the levels of IL-10 increased (P < 0.05).

Conclusion: Doxofylline might attenuate pulmonary inflammatory responses in mechanically ventilated rats with COPD, and the JNK/stress-activated protein kinase signaling pathway is involved in doxofylline's inhibition of inflammatory responses in the pulmonary tissue of rats with COPD.

Citing Articles

The effects of camel milk in systemic inflammation and oxidative stress of cigarette smoke-induced chronic obstructive pulmonary disease model in rat.

Behrouz S, Mohammadi M, Sarir H, Boskabady M Front Vet Sci. 2024; 11:1464432.

PMID: 39735585 PMC: 11673985. DOI: 10.3389/fvets.2024.1464432.

Camel milk inhibits pulmonary oxidative stress and inflammation in a rat model of COPD induced by cigarette smoke exposure.

Behrouz S, Mohammadi M, Sarir H, Mohammadian Roshan N, Boskabady M Heliyon. 2024; 10(20):e39416.

PMID: 39497967 PMC: 11532301. DOI: 10.1016/j.heliyon.2024.e39416.

Correction: Effect of doxofylline on pulmonary inflammatory response and oxidative stress during mechanical ventilation in rats with COPD.

Chen Z, Lin Y, Wu J, Zhang X, Zhang Y, Xie W BMC Pulm Med. 2024; 24(1):234.

PMID: 38745138 PMC: 11412036. DOI: 10.1186/s12890-024-03049-y.

Roles of autophagy-related genes in the therapeutic effects of Xuanfei Pingchuan capsules on chronic obstructive pulmonary disease based on transcriptome sequencing analysis.

Zhang Y, Xue X, Meng L, Li D, Qiao W, Wang J Front Pharmacol. 2023; 14:1123882.

PMID: 37274101 PMC: 10232735. DOI: 10.3389/fphar.2023.1123882.

References

Ezzati Givi M, Redegeld F, Folkerts G, Mortaz E . Dendritic cells in pathogenesis of COPD. Curr Pharm Des. 2012; 18(16):2329-35. DOI: 10.2174/138161212800166068. View

Lal D, Manocha S, Ray A, Vijayan V, Kumar R . Comparative study of the efficacy and safety of theophylline and doxofylline in patients with bronchial asthma and chronic obstructive pulmonary disease. J Basic Clin Physiol Pharmacol. 2015; 26(5):443-51. DOI: 10.1515/jbcpp-2015-0006. View

Matera M, Page C, Cazzola M . Doxofylline is not just another theophylline!. Int J Chron Obstruct Pulmon Dis. 2017; 12:3487-3493. PMC: 5723117. DOI: 10.2147/COPD.S150887. View

Schluger N, Koppaka R . Lung disease in a global context. A call for public health action. Ann Am Thorac Soc. 2014; 11(3):407-16. DOI: 10.1513/AnnalsATS.201312-420PS. View

Duell B, Tan C, Carey A, Wu F, Cripps A, Ulett G . Recent insights into microbial triggers of interleukin-10 production in the host and the impact on infectious disease pathogenesis. FEMS Immunol Med Microbiol. 2012; 64(3):295-313. DOI: 10.1111/j.1574-695X.2012.00931.x. View

Suki B . Fluctuations and power laws in pulmonary physiology. Am J Respir Crit Care Med. 2002; 166(2):133-7. DOI: 10.1164/rccm.200202-152pp. View

Cazzola M, Calzetta L, Barnes P, Criner G, Martinez F, Papi A . Efficacy and safety profile of xanthines in COPD: a network meta-analysis. Eur Respir Rev. 2018; 27(148). PMC: 9488859. DOI: 10.1183/16000617.0010-2018. View

Chen Z, Zhang Y, Wu J, Gao X, Huang C, Lin Y . The Mechanism of Penehyclidine Hydrochloride and Its Effect on the Inflammatory Response of Lung Tissue in Rats with Chronic Obstructive Pulmonary Disease During Mechanical Ventilation. Int J Chron Obstruct Pulmon Dis. 2021; 16:877-885. PMC: 8020330. DOI: 10.2147/COPD.S295329. View

Riffo-Vasquez Y, Man F, Page C . Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014; 27(2):170-8. DOI: 10.1016/j.pupt.2014.01.001. View

10.

Churg A, Cosio M, Wright J . Mechanisms of cigarette smoke-induced COPD: insights from animal models. Am J Physiol Lung Cell Mol Physiol. 2008; 294(4):L612-31. DOI: 10.1152/ajplung.00390.2007. View

11.

Rao R, Guru Prasad K, Gangu Naidu C, Saida S, Agwane S . Development of a validated LC-MS/MS method for determination of doxofylline on rat dried blood spots and urine: application to pharmacokinetics. J Pharm Biomed Anal. 2013; 78-79:211-6. DOI: 10.1016/j.jpba.2013.02.017. View

12.

Fu J, McDonald V, Baines K, Gibson P . Airway IL-1β and Systemic Inflammation as Predictors of Future Exacerbation Risk in Asthma and COPD. Chest. 2015; 148(3):618-629. DOI: 10.1378/chest.14-2337. View

13.

Vestbo J, Hurd S, Agusti A, Jones P, Vogelmeier C, Anzueto A . Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2012; 187(4):347-65. DOI: 10.1164/rccm.201204-0596PP. View

14.

Beckett E, Stevens R, Jarnicki A, Kim R, Hanish I, Hansbro N . A new short-term mouse model of chronic obstructive pulmonary disease identifies a role for mast cell tryptase in pathogenesis. J Allergy Clin Immunol. 2013; 131(3):752-62. PMC: 4060894. DOI: 10.1016/j.jaci.2012.11.053. View

15.

Zhang Y, Zeng K, Wang J, Gao H, Nan Y, Zheng X . Identifying the antiasthmatic target of doxofylline using immobilized β2 -adrenoceptor based high-performance affinity chromatography and site-directed molecular docking. J Mol Recognit. 2016; 29(10):492-8. DOI: 10.1002/jmr.2549. View

16.

Li C, Shi Q, Yan Y, Kong Y, Meng Y, Wang T . Recuperating Lung Decoction Attenuates the Oxidative Stress State of Chronic Obstructive Pulmonary Disease by Inhibiting the MAPK/AP-1 Signal Pathway and Regulating -GCS. Evid Based Complement Alternat Med. 2017; 2017:9264914. PMC: 5376952. DOI: 10.1155/2017/9264914. View

17.

Tang W, Xie J, Xu S, Lv H, Lin M, Yuan S . Novel nitric oxide-releasing derivatives of brusatol as anti-inflammatory agents: design, synthesis, biological evaluation, and nitric oxide release studies. J Med Chem. 2014; 57(18):7600-12. DOI: 10.1021/jm5007534. View

18.

Luo B, Niu R, Feng J, Hu C, Xie X, Ma L . Downregulation of secretory leukocyte proteinase inhibitor in chronic obstructive lung disease: the role of TGF-beta/Smads signaling pathways. Arch Med Res. 2008; 39(4):388-96. DOI: 10.1016/j.arcmed.2008.02.002. View

19.

Kastelik J, Aziz I, Ojoo J, Morice A . Evaluation of impulse oscillation system: comparison with forced oscillation technique and body plethysmography. Eur Respir J. 2002; 19(6):1214; author reply 1214-5. DOI: 10.1183/09031936.02.01922001. View